




## SEMINARIO

# Ketones in Cardiovascular Disease and Diabetes: from Bench to Bedside



**Angela Lombardi**

**Assistant Professor of Advanced Medical and Surgical  
Technology and Methodology**

Ketone bodies are molecules produced from fatty acids in the liver that act as energy carriers to peripheral tissues when glucose levels are low. Of note, Sodium-Glucose Transporter 2 (SGLT2) inhibitor treatment increases the levels of beta-hydroxybutyrate (BHB), the most abundant ketone circulating in the human body, which may play a pivotal role in mediating some of their protective effects in cardiovascular health and diabetes. The evidence from animal and human studies indicates that exogenous ketones may have significant beneficial effects on both cardiomyocytes and pancreatic beta cells, making them intriguing candidates for potential cardioprotective therapies and to preserve beta cell function in diabetic patients.

**Mercoledì 12 febbraio 2025 ore 14:00**

Dipartimento di Medicina Clinica e Molecolare

Aula 2 Facoltà di Medicina e Psicologia

[Via Giorgio Nicola Papanicolau](#) Roma